Dupilumab improves disease control and patient-reported outcomes in adults with atopic dermatitis in clinical practice: Subgroup analysis of Black/African American population from RELIEVE-AD Raj Chovatiya,¹ Jingdong Chao,² Chien-Chia Chuang,³ Min Yang,⁴ Brad Shumel,² Bruno Martins,⁴ Gaelle Bégo-Le-Bagousse,⁵ Debra Sierka,³ Dimittri Delevry²

¹Northwestern University Feinberg School of Medicine, Chicago, IL, USA; ²Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA; ³Sanofi, Cambridge, MA, USA; ⁴Analysis Group Inc., Boston, MA, USA; ⁵Sanofi, Chilly-Mazarin, France

INTRODUCTION

• Atopic dermatitis (AD) is a chronic, type 2 inflammatory skin disease associated

RESULTS (CONT.)

Figure 2. Disease Control Status by ADCT Total Score


- with persistent symptoms of itch, skin pain, and sleep disturbances¹
- Dupilumab is a fully human anti-interleukin-4 receptor α monoclonal antibody approved for patients aged ≥ 6 months with moderate-to-severe AD inadequately controlled by topical therapies^{2,3}
- The safety and efficacy of dupilumab have been demonstrated in phase 3 clinical trials⁴⁻¹²
- prospective, real-world, longitudinal patient survey study, RELIEVE-AD, demonstrated that dupilumab treatment leads to rapid and sustained disease control, and improves patient-reported AD-related sleep problems and skin symptoms in adults with moderate-to-severe AD¹³
- A subgroup analysis of patient-reported outcomes (PRO) was conducted in Black/ African American adults with AD from the RELIEVE-AD study

OBJECTIVE

• To evaluate the real-world effectiveness of dupilumab on disease control and AD-related symptoms from the perspective of Black/African American patients, a population in which clinical study data are limited

 Table 1. Baseline Demographic and Clinical Characteristics of
Black/African American Adults with AD

Variable	Baseline (N = 64)	Month 12 (N = 43)				
Female, n (%)	55 (85.9)	37 (86.0)				
Age, mean (SD)	38.2 (13.8)	38.8 (13.8)				
Geographic region, n (%)						
Northeast	10 (15.6)	8 (18.6)				
Midwest	7 (10.9)	4 (9.3)				
South	40 (62.5)	25 (58.1)				
West	7 (10.9)	6 (14.0)				
Age at AD diagnosis, n (%)						
≤18 years	37 (57.8)	28 (65.1)				
19–34 years	9 (14.1)	6 (14.0)				
≥35 years	11 (17.2)	7 (16.3)				
Don't remember	7 (10.9)	2 (4.7)				
Education, n (%)						
High school diploma or equivalent	12 (18.8)	5 (11.6)				
Some college or Associate's degree	30 (46.9)	18 (41.9)				
College graduate/Bachelor's degree	14 (21.9)	13 (30.2)				
Advanced degree (such as Master's degree, professional degree beyond undergraduate, or Doctorate degree)	8 (12.5)	7 (16.3)				
Comorbidities,* n (%)						
Type 2 comorbid diseases (asthma or non-seasonal allergies)	39 (60.9)	27 (62.8)				
Seasonal allergies	36 (56.3)	25 (58.1)				
Non-seasonal allergies [†]	26 (40.6)	19 (44.2)				
Asthma	24 (37.5)	15 (34.9)				
Hypertension (high blood pressure)	16 (25.0)	13 (30.2)				
Anxiety	15 (23.4)	8 (18.6)				
Depression	11 (17.2)	7 (16.3)				
Obesity	17 (26.6)	12 (27.9)				
Sleep disorders	6 (9.4)	6 (14.0)				
Anemia	18 (28.1)	12 (27.9)				
Diabetes mellitus (type 1 or 2)	7 (10.9)	6 (14.0)				
AD, atopic dermatitis; SD, standard deviation. *Defined as ≥10% among all patients. Responses were not mutually exclusive.						



ADCT total score ranges from 0–24 with a higher score indicating worse AD control. Disease control is defined as total score <7. *P*<0.0001 vs BL

Sleep Problems

• AD-related sleep problems were significantly decreased, from 73.4% of patients at baseline to 29.4% at Month 1, and 18.6% at Month 12 (both *P*<0.0001; Figure 3)

Fig	Figure 3. Sleep Problems Due to AD												
1	⁸⁰ 7	73.4											
%	70 -												
•	60 -												
patients	50 -												
	40 -		*	*	*	*	*						


METHODS

- In the RELIEVE-AD study, adults with moderate-to-severe AD were identified through the US dupilumab patient support program and invited to participate in an online survey before (baseline) and after dupilumab initiation at Months 1, 2, 3, 6, 9, and 12^{13}
- AD disease control was assessed using the AD Control Tool (ADCT; range, 0–24), where a total score <7 indicates disease control
- AD-related sleep problems were assessed using a stand-alone question, "Over the last week, did you experience sleep problems because of your AD?" with response options of Yes or No
- Skin symptoms (skin pain, burning, sensitivity) were assessed using a numerical rating scale (range 0 [no symptoms] to 10 [worst symptom severity]) at baseline and through Month 12
- A subgroup analysis of self-reported data from the Black/African American population was performed

RESULTS

Patient Characteristics

[†]Allergic rhinitis, allergic conjunctivitis, food allergies, allergic urticaria or hives, and others





Skin Symptoms

• Symptom scores for skin pain, burning, and sensitivity significantly improved from baseline to Month 1, and through Month 12 (all P<0.0001; Figure 4)

Figure 4. Symptom Scores for AD-related Skin Pain, Burning, and Sensitivity



- Of 64 Black/African American patients completing the baseline survey, 43 provided responses at Month 12, with a survey completion rate of 67.2%
- Among patients who completed the survey at Month 12 (N = 43), mean age at study initiation was 38.8 years and a majority of patients were female (Table 1)

Disease Control

- Mean total ADCT score was significantly decreased from 16.8 at baseline to 7.3 at Month 1 and was further reduced to 4.9 at Month 12 (both *P*<0.0001; Figure 1)
- Disease control was significantly improved at Month 1 and through Month 12 compared with baseline (both *P*<0.0001; **Figure 2**)

ADCT. Atopic Dermatitis Control Tool: BL. baseline: M. month: SD. standard deviation ADCT total score ranges from 0–24 with a higher score indicating worse AD control. Disease control is defined as total score <7. *P<0.0001 vs BL.

	BL	M1	M2	M3	M6	M9	M12	BL	M1	M2	M3	M6	M9	M12	BL	M1	M2	M3	M6	M9	M12	
N =	64	51	56	53	51	46	43	64	51	56	53	51	46	43	64	51	56	53	51	46	43	
Skin pain					Skin feeling hot/burning								Skin	sensi	tivity							

AD, atopic dermatitis: BL, baseline: M, month. Symptom score range for each category was 0-10; a score of 0 indicates no symptoms. Each category asked the patient to recall the average level over the past week. *P<0.0001 vs BL.

CONCLUSIONS

- In Black/African American adults with moderate-to-severe AD, treated with dupilumab, significant and rapid improvements in disease control, sleep problems, and skin symptoms were observed
- Improvements in disease control and PRO were sustained over the 1-year study period
- Interpretation of the results of this subgroup analysis should account for the small sample size and attrition over the study period

References: 1. Wittkowski A, et al. Psychol Health Med 2007;12(4):433-444. 2. Dupixent[®] (dupilumab). Highlights of prescribing information. https://www.ema.europa.eu/en/documents/product-fpi.pdf. Accessed August 8, 2023. 3. Dupixent[®] (dupilumab). Highlights of prescribing information. https://www.ema.europa.eu/en/documents/product-fpi.pdf. Accessed August 8, 2023. 3. Dupixent[®] (dupilumab). Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-fpi.pdf. Accessed August 8, 2023. 3. Dupixent[®] (dupilumab). Highlights of prescribing information. https://www.ema.europa.eu/en/documents/product-fpi.pdf. Accessed August 8, 2023. 3. Dupixent[®] (dupilumab). Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-fpi.pdf. Accessed August 8, 2023. 3. Dupixent[®] (dupilumab). Highlights of prescribing information. https://www.ema.europa.eu/en/documents/product-fpi.pdf. Accessed August 8, 2023. 3. Dupixent[®] (dupilumab). Highlights of prescribing information. https://www.ema.europa.eu/en/documents/product-fpi.pdf. Accessed August 8, 2023. 3. Dupixent[®] (dupilumab). Highlights of prescribing information. https://www.ema.europa.eu/en/documents/product-fpi.pdf. Accessed August 8, 2023. 3. Dupixent[®] (dupilumab). Highlights of prescribing information. https://www.ema.europa.eu/en/documents/product-fpi.pdf. Accessed August 8, 2023. 3. Dupixent[®] (dupilumab). Highlights of prescribing information. https://www.ema.europa.eu/en/documents/product-fpi.pdf. Accessed August 8, 2023. 3. Dupixent[®] (dupilumab). Highlights of prescribing information. https://www.ema.europa.eu/en/documents/product-fpi.pdf. Accessed August 8, 2023. 3. Dupixent[®] (dupilumab). Highlights 6, 2023. 3. Dupixent[®] information/dupixent-epar-product-information_en.pdf. Accessed August 8, 2023. 4. Simpson EL, et al. *J Am Acad Dermatol* 2020;82(2):377-388. 7. Simpson EL, et al. *JAMA Dermatol* 2020;156(1):44-56. 8. Cork MJ, et al. Br J Dermatol 2020;182(1):85-96. 9. Paller AS, et al. JAm Acad Dermatol 2022;400(10356):908-919. 12. Blauvelt A, et al. Am J Clin Dermatol 2022;23(3):365-383. 13. Strober B, et al. JAMA Dermatol 2022;158(2):142-150. Acknowledgments: Research sponsored by Sanofi and Regeneron Pharmaceuticals Inc. According to the Good Publication Practice guideline. Copyediting and formatting assistance was provided by Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals Inc.

Disclosures: Dr Chovatiya served as a consultant, advisory board member, and/or investigator for AbbVie, Arcutis Biotherapeutics, Arena Pharmaceuticals, Argenx, Beiersdorf, Bristol-Myers Squibb, Dermavant, EPI Health, Incyte, L'Oréal, Lilly, National Eczema Association, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi, and UCB Pharma. CC, GBLB, and DS are employees of, and stockholders in, Sanofi. MY and BM are employees of Analysis Group Inc., Boston, MA, USA, a company that received research funds from Sanofi/Regeneron Pharmaceuticals Inc.

Presented at the 42nd Fall Clinical Dermatology Conference; Las Vegas, NV, USA; October 20–23, 2022.

